Product image of Mozobil (Plerixafor) supplied by GNH India

Mozobil

Active Ingredient:
Plerixafor
Origin:
EU

Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It mobilizes hematopoietic stem cells for autologous transplantation in patients with non‑Hodgkin lymphoma or multiple myeloma. Mozobil is authorized in the European Union and is supplied as a sterile, preservative‑free solution for clinical use.

GNH India supplies Mozobil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Manufacturer / TM Owner

Sanofi B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mozobil is employed to mobilize hematopoietic stem cells in hematologic malignancies.

  • Non‑Hodgkin lymphoma: mobilizes stem cells to enable collection for autologous transplantation.
  • Multiple myeloma: mobilizes stem cells to enable collection for autologous transplantation.
  • Hematopoietic stem cell mobilization: enhances peripheral blood CD34+ cell yield to meet collection targets for autologous transplant procedures.

How It Works

  • Plerixafor antagonizes the CXCR4 receptor, disrupting the interaction between stromal cell‑derived factor‑1 (SDF‑1) and CXCR4 on hematopoietic stem cells. This inhibition releases stem cells from the bone‑marrow niche into the peripheral circulation, increasing the number of CD34+ cells available for collection prior to autologous transplantation.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Injection site reactions: pain, erythema, or swelling at the subcutaneous site.
  • Diarrhea: loose stools occurring shortly after administration.
  • Fatigue: transient tiredness reported by many patients.
  • Headache: mild to moderate intensity.
  • Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects

  • Splenic rupture: rare but potentially life‑threatening abdominal event.
  • Severe allergic reaction: anaphylaxis with rash, bronchospasm, or hypotension.
  • Severe hypotension: marked drop in blood pressure requiring monitoring.
  • Leukocytosis: marked increase in white blood cell count.
  • Severe bone pain: intense musculoskeletal discomfort.
  • Tumor flare: rapid progression of underlying disease in rare cases.

Precautions & Warnings

Prior to administration, clinicians should consider several safety measures.

  • Assess baseline CD34+ count: ensure adequate stem cell reserve before dosing.
  • Monitor for splenic enlargement: perform imaging if patients report abdominal pain.
  • Evaluate renal function: adjust use in patients with severe impairment.
  • Avoid concurrent use with other CXCR4 antagonists unless directed.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mozobil may interact with other agents that affect stem cell dynamics or hemostasis.

Major Interactions (Avoid)

  • Co‑administration with other CXCR4 antagonists: may cause excessive stem cell mobilization.
  • Use with investigational agents that alter bone‑marrow niche: risk of unpredictable hematologic effects.

Moderate Interactions (Monitor Closely)

  • Concurrent granulocyte‑colony stimulating factor (G‑CSF): may increase leukocytosis.
  • Anticoagulants or antiplatelet drugs: heightened risk of injection‑site bleeding.
  • Diuretics: potential fluid‑balance changes influencing subcutaneous absorption.

Frequently Asked Questions

Mozobil is used to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood, allowing collection of CD34+ cells for autologous transplantation in patients with non‑Hodgkin lymphoma or multiple myeloma.

Plerixafor blocks the CXCR4 receptor, preventing the binding of stromal cell‑derived factor‑1 (SDF‑1). This disruption releases stem cells from their marrow niche, increasing their numbers in the bloodstream for collection.

The prescribed dose of Mozobil is determined by the treating physician based on patient weight, disease status, and concurrent therapies. It is administered as a subcutaneous injection under clinical supervision.

Safety of Mozobil in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant.

To order Mozobil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative for stem cell mobilization is granulocyte‑colony stimulating factor (G‑CSF) alone. Mozobil, as a CXCR4 antagonist, can be combined with G‑CSF to achieve higher CD34+ yields, especially in patients who respond poorly to G‑CSF monotherapy.

Mozobil must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until ready for use.

Mozobil is given as a single subcutaneous injection, usually 10–11 minutes before the planned stem cell collection procedure. The injection site is typically the abdomen or thigh, and the volume is based on the prescribed dose.

Serious risks include splenic rupture, severe allergic reactions (anaphylaxis), marked hypotension, and rare events such as tumor flare. Patients should be monitored closely for abdominal pain, signs of hypersensitivity, and sudden drops in blood pressure.

Mozobil is contraindicated in patients with known hypersensitivity to plerixafor or any excipients, and it should be used with caution in individuals with severe splenomegaly or significant renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Plerixafor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT